Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CYP3A5 Antibodies:
anti-Cow (Bovine) CYP3A5 Antibodies:
anti-Mouse (Murine) CYP3A5 Antibodies:
Go to our pre-filtered search.
our findings suggest that CYP1A2 (show CYP1A2 Antibodies), CYP3A4 (show CYP3A4 Antibodies) and CYP3A5 play an important role in osteosarcoma tumorigenesis, at primary and metastatic sites, as well in treatment response
Patients with both CYP3A5*3/*3 and MDR1 (show TBC1D9 Antibodies) G2677A who underwent renal transplantation had higher blood TAC (show IL2RA Antibodies) concentrations than those without those genotypes. Japanese patients should be carefully monitored for consideration of lower TAC (show IL2RA Antibodies) doses, because 24% of Japanese patients have double mutations.
Among two SNPs in CYP3A4 (show CYP3A4 Antibodies) and CYP3A5 and 12 SNPs in ABCB1 (show ABCB1 Antibodies) gene, an association with ovarian cancer risk was observed for ABCB1 (show ABCB1 Antibodies) rs2157926 SNP only.
Donor CYP3A5 genotype, recipient age and, to a lesser extent, donor gender appear to be associated with tacrolimus disposition on day 1 after transplant
The CYP3A5*3 gene polymorphism was closely associated with the mRNA expression of CYP3A5, CYP3A enzyme activity and DNR plasma drug concentration, and exhibited different drug adverse reactions.
Cryopreserved human hepatocytes can be stored stably for more than a decade with little or no change in CYP3A4 (show CYP3A4 Antibodies)/5 induction.
Associations between SLCO1B1 (show SLCO1B1 Antibodies) 521C and cholesterol response were not detected in African Americans (n = 333). Associations between CYP3A4 (show CYP3A4 Antibodies)*22 or CYP3A5*3 and cholesterol response were not detected in whites or African Americans.
The CYP3A5 genotype had no impact on the concentrations of cyclosporine A and tacrolimus at any investigated time point
We confirmed CYP3A5 metabolic activity with the CYP3A4 (show CYP3A4 Antibodies) selective inhibitor CYP3CIDE.
Part of the differences in tacrolimus pharmacokinetics and transplantation outcomes may relate to differences between populations in the genetics of tacrolimus-metabolizing enzymes. The best-known example is the allelic frequency of the loss-of-function CYP3A5*3 allele.
This gene,CYP3A5, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. The enzyme metabolizes drugs such as nifedipine and cyclosporine as well as the steroid hormones testosterone, progesterone and androstenedione. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. This cluster includes a pseudogene, CYP3A5P1, which is very similar to CYP3A5. This similarity has caused some difficulty in determining whether cloned sequences represent the gene or the pseudogene. Multiple alternatively spliced transcript variants have been identified for this gene.
cytochrome P450 3A5
, aryl hydrocarbon hydroxylase
, cytochrome P450 HLp2
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5
, cytochrome P450-PCN3
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase